COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

The Efficacy and Safety of Sirolimus -Coated Balloon (SeQuent® SCB) in Treatment of Patients With Coronary ISR

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04240444
Recruitment Status : Not yet recruiting
First Posted : January 27, 2020
Last Update Posted : February 19, 2020
CCRF Inc., Beijing, China
Information provided by (Responsible Party):
B. Braun Medical International Trading Company Ltd.

Brief Summary:
This is a prospective, multicenter, randomized controlled clinical trial, which plans to enroll 260 subjects.

Condition or disease Intervention/treatment Phase
Coronary Artery Disease In Stent Restenosis Device: drug-coated balloon Catheter Not Applicable

Detailed Description:

This is a prospective, multicenter, randomized (1:1) controlled clinical trial, which plans to enroll 260 subjects. The aim of study is to assess the safety and efficacy of SeQuent® SCB in the treatment of in-stent restenosis in coronary arteries.

All eligible subjects with ISR lesion in coronary will be randomly assigned to receive SeQuent® SCB (study group) or receive SeQuent® Please Neo (control group) balloon treatment. All subjects will be scheduled to clinical follow up at 30 days, 6 months, 9 months and 12 months after index procedure and will be scheduled to receive the angiography at 9 months after index procedure. The primary endpoint was segment late luminal loss at 9 months after index procedure.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 260 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Prospective, Multicenter, Randomized Controlled Clinical Trial to Assess the Safety and Efficacy of SeQuent® SCB Balloon in the Treatment of Patients With Coronary Arteries In-stent Restenosis Compared SeQuent® Please Neo
Estimated Study Start Date : March 2020
Estimated Primary Completion Date : January 2022
Estimated Study Completion Date : July 2022

Arm Intervention/treatment
Experimental: SeQuent® SCB
patients will receive sirolimus (rapamycin)-coated balloon (SeQuent® SCB)
Device: drug-coated balloon Catheter
All eligible subjects will be assigned randomly to study group or control group, receive PTCA.

Active Comparator: SeQuent® Please Neo
patients will receive SeQuent® Please Neo balloon
Device: drug-coated balloon Catheter
All eligible subjects will be assigned randomly to study group or control group, receive PTCA.

Primary Outcome Measures :
  1. In-segment late loss [ Time Frame: at 9 months after index procedure ]
    In-segment late loss(LLL) is defined as the difference between the MLD immediately after the procedure and the MLD at 9-month follow-up angiography after index procedure. MLDs are measured by QCA.

Secondary Outcome Measures :
  1. The success rate of intervention treatment [ Time Frame: 1-3 days ]
    including device success, lesion success and clinical success

  2. Binary restenosis rate of target lesion [ Time Frame: 9 months after index procedure ]
    A diameter stenosis of > 50% at the previously treated lesion site, including the originally treated site plus the adjacent vascular segments 5 mm , proximal and 5 mm distal to the site . Percent diameter stenosis was defined as [1(MLD/reference vessel diameter)]100.

  3. Target lesion failure (TLF) rate [ Time Frame: 30 days, 6 months, 9 moths, 12 months after index procedure ]
    The composite of ischemia-driven revascularization of the target lesion, MI related to the target vessel, or cardiac death related to the target vessel

  4. PoCE [ Time Frame: 30 days, 6 months, 9 moths, 12 months after index procedure ]
    a composite of all death, MI and any revascularization

  5. ARC-defined stent thrombosis [ Time Frame: 30 days, 6 months, 9 moths, 12 months after index procedure ]
    timing (acute, subacute, late and very late stent thrombosis); relationship (definite, probable and possible stent thrombosis)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • General criteria

    1. Patient ≥18 years of age.
    2. Stable angina pectoris or unstable angina pectoris (acute coronary syndrome), prior myocardial infarction or proven asymptomatic myocardial ischemia.
    3. Patients are eligible for any type of coronary revascularization.
    4. Patients agree to receive angiography follow-up at 9 months after index procedure.
    5. Patients agree to receive clinical follow-up at 30 days, 6months, 9 months and 1years after index procedure.
    6. Patients are able to understand the purpose of the study and will comply with the study protocol. The patient is willing to sign informed consent form and understand the risks and benefits described in the informed consent form.
  • lesion related

    1. Up to 2 ISR lesions which found by angiography (diameter stenosis ≥70% or ≥ 50% with evidence of ischemia) or functional examination (e.g. FFR<0.8 IVUS<4mm2) will be treated, target segment includes news lesions within 5mm of the stent margin.
    2. Up to 2 drug coated balloons (SeQuent® Please Neo or SeQuent® SCB) will be used in the study, with 1 drug coated balloon per lesion.
    3. ISR (including bare stents, inert and active drug eluting stents) : Mehran type I, II and III stenosis; The reference vessel diameter of target lesions ranges from 2.5mm to 4.0mm (visual), and the length of each lesion are≤ 34mm (visual).
    4. Other de novo lesions needing treatment must be >10mm away from the target lesion.

Exclusion Criteria:

  • General criteria

    1. Patients with myocardial infarction within 1 week before index procedure.
    2. Patients with takayasu arteritis.
    3. Patients with severe renal failure, whose Creatinine >2.0 mg/dL (177 mol/L).
    4. LVEF<30%.
    5. Hb before procedure <10 g/dL.
    6. Patients with Coagulation disorder, platelet count <100,000/mm3.
    7. Patients with cardiogenic shock.
    8. Patients with diseases who require cytostatic or radiotherapy.
    9. Patients who are known to be allergic or contraindicated to aspirin, heparin, clopidogrel, rapamycin, ticagrelor, tirofiban, paclitaxel, or iopromide , or who are allergic to contrast agents and cannot be medically prevented, or who are on cilostazol anticoagulants.
    10. Patients with bleeding conditions, or with conditions that increase the risk of bleeding, such as gastrointestinal ulcers, which may be restricted or prohibited from anticoagulant therapy or the use of anticoagulant drugs.
    11. Gestational women who were pregnant before receiving treatment with the study device or who planned to be pregnant during the study , and did not use effective contraception until (including) follow-up at 12 months postoperatively; Female patients during lactation.
    12. Patients with a life expectancy less than 1 year.
    13. Patients who are participating in any other clinical trial.
    14. Investigator considered the patients ineligible due to any reasons.
  • lesion related

    1. There are more than 3 lesions to be treated (including non-target lesions to be treated), and there are more than 2 lesions to be treated in each coronary artery.
    2. There will be more than 5 stents implanted in coronary artery after intervention (including previous and current PCI).
    3. After pre-dilatation of target lesion, there will be residual stenosis of target lesion >30% or TIMI blood flow < grade 3, and/ dissections NHLBI grade C,D,E,F.
    4. The ISR lesion has been treated in past 6 months.
    5. The target lesion is tortuous, severely calcified, angular, and the DCB is expected to be impassable.
    6. Target lesion contains thrombosis.
    7. Target or non-target lesion(s) located in left main.
    8. Patients with previous CABG.
    9. Patients with lesions requiring intervention treatment in 3 vessels

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04240444

Show Show 19 study locations
Sponsors and Collaborators
B. Braun Medical International Trading Company Ltd.
CCRF Inc., Beijing, China
Layout table for investigator information
Principal Investigator: Yaling Han, academician General Hospital of Northern Theater Command
Layout table for additonal information
Responsible Party: B. Braun Medical International Trading Company Ltd. Identifier: NCT04240444    
Other Study ID Numbers: AAG-G-H-1905
First Posted: January 27, 2020    Key Record Dates
Last Update Posted: February 19, 2020
Last Verified: January 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronary Artery Disease
Coronary Disease
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases